Growth of $23 billion by the year 2021 is anticipated in the global cholesterol-lowering drugs market, according to a new report from business intelligence provider, Visiongain. more


Research, recently presented at the EuroCMR 2017 congress, has suggested that statins are associated with improved heart structure and function, with benefits that were above and beyond the cholesterol lowering effects of the drugs. more


The cheap anti-cholesterol drug group, statins, are going to be used in a six-year trial to establish whether they can slow the progression of multiple sclerosis (MS). more


A recent study, published in the Lancet, suggests that common side effects of statins, namely muscle pain and weakness, are not directly a result of the drugs but more because of patients’ negative expectations. more


This collaboration will provide clinicians and physicians with newly developed genetic tests and a decision support system that will allow them to manage statins, prescribe and dose these drugs on a DNA-guided, personalised basis. more